| Literature DB >> 28915230 |
Meng-Jie Huang1, Ri-Bao Wei1, Jing Zhao1, Ting-Yu Su1, Qing-Ping Li1, Xi Yang1, Xiang-Mei Chen1.
Abstract
BACKGROUND Albuminuria has been associated with cardiovascular events, but whether such an association can be explained by endothelial dysfunction is not fully understood. In this study, we examined the relationship between the urine albumin-to-creatinine ratio (UACR) and biomarkers of endothelial function in patients with chronic kidney disease (CKD). MATERIAL AND METHODS The cross-sectional associations of renal dysfunction and UACR with procoagulant and inflammatory factors were evaluated for 151 consecutive CKD (stage 3-5) patients. Subjects were grouped by UACR (≤300 mg/g or >300 mg/g) and estimated glomerular filtration rate (eGFR) (30≤ eGFR <60, 15≤ eGFR <30, or eGFR <15 ml/min per 1.73 m²). RESULTS A higher UACR level was associated with an increase in von Willebrand factor antigen (vWF: Ag) levels, vWF activity, factor VIII, interleukin-2, and log (interleukin-6), even after adjustment for risk factors. Linear regression analysis indicated that for every 88.5 mg/g increase in UACR, the vWF activity and factor VIII were elevated by 8.3% and 6.3%, respectively. The factorial design ANOVA data showed no statistically significant interaction between UACR and CKD stage with procoagulant and inflammatory factors. CONCLUSIONS Our study shows an eGFR-independent association of higher UACR with elevations in markers of endothelial dysfunction and inflammatory factors in CKD patients.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28915230 PMCID: PMC5612264 DOI: 10.12659/msm.903660
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1The flow chart of the study.
Baseline characteristics of the study cohort.
| Variables | CKD patients (n=151) | Urine albumin-to-creatinine ratio ≤300 mg/g (n=79) | Urine albumin-to-creatinine ratio >300 mg/g (n=72) | P |
|---|---|---|---|---|
| Gender, M, n (%) | 95 (63%) | 58 (73%) | 37 (51%) | 0.013 |
| Age (year) | 43.6±12.9 | 41.6±12.6 | 45.9±13.0 | 0.121 |
| Body mass index (kg/m2) | 24.6±3.7 | 24.2±3.3 | 24.9±4.1 | 0.475 |
| Mean arterial pressure (mmHg) | 98.1±11.6 | 96.6±13.2 | 99.7±9.2 | 0.264 |
| Hemoglobin (g/L) | 118.5±21.5 | 124.2±22.0 | 112.3±19.3 | 0.003 |
| Platelet count (109/l) | 212.2±57.3 | 203.5±51.2 | 221.8±62.4 | 0.147 |
| White blood cell count (109/l) | 7.1±1.9 | 7.0±1.7 | 7.3±2.1 | 0.747 |
| Serum albumin (g/L) | 39.9±4.0 | 40.9±3.5 | 38.7±4.1 | 0.004 |
| eGFR (ml/min/1.73 m2) | 30.9±17.7 | 36.7±19.6 | 24.4±12.6 | <0.001 |
| CKD3 stage, N (%) | 58 (38%) | 43 (54%) | 15 (21%) | <0.001 |
| CKD4 stage, N (%) | 55 (36%) | 23 (29%) | 32 (44%) | 0.148 |
| CKD5 stage, N (%) | 38 (25%) | 13 (16%) | 25 (35%) | 0.036 |
| Cholesterol (mmol/l) | 4.2±0.9 | 4.0±1.0 | 4.3±0.8 | 0.161 |
| Triglycerides (mmol/l) | 2.0±0.9 | 2.0±0.9 | 2.0±0.9 | 0.999 |
Data are expressed as mean ± standard deviation (SD) or median (interquatile range) as appropriate; eGFR – estimated glomerular filtration rate; CKD – chronic kidney disease.
P<0.05, vs. CKD group;
P<0.05, vs. UACR >300 mg/g group.
Unadjusted and adjusted levels of procoagulant and inflammatory biomarkers.
| Variables | Unadjusted | P | Multivariable-adjusted | P | ||
|---|---|---|---|---|---|---|
| Urine albumin-to-creatinine ratio ≤300 mg/g | Urine albumin-to-creatinine ratio >300 mg/g | Urine albumin-to-creatinine ratio ≤300 mg/g | Urine albumin-to-creatinine ratio >300 mg/g | |||
| VWF: Ag (%) | 140.2±51.7 | 181.7±45.7 | <0.001 | 145.1±49.2 | 177.9±49.7 | <0.001 |
| VWF: activity (%) | 131.2±49.2 | 176.9±47.9 | <0.001 | 135.4±49.2 | 173.6±49.7 | <0.001 |
| Factor VIII (%) | 120.6±29.7 | 142.5±23.7 | <0.001 | 124.3±25.2 | 137.6±25.6 | 0.030 |
| IL-2 (U/ml) | 728.5±201.7 | 880.2±233.4 | 0.004 | 748.3±172.2 | 859.5±180.0 | 0.044 |
| Log(IL-6 (pg/ml)) | 0.53±0.3 | 0.78±0.3 | <0.001 | 0.57±0.3 | 0.75±0.3 | 0.007 |
| SOD (U/ml) | 151.7±21.5 | 135.1±14.7 | 0.001 | 148.1±14.7 | 138.8±15.3 | 0.036 |
IL – Interleukin; SOD – Superoxide dismutase.
Adjusted for age, sex, mean arterial pressure, body mass index, hemoglobin, serum albumin, cholesterol, triglycerides, and eGFR.
Association of eGFR and UACR with endothelial dysfunction: difference in hemostatic marker per 10 ml/min/1.73 m2 decrease in eGFR and per 88.5-U increase of UACR.
| Cohort and variables | Unadjusted changes (95% CI) | P | Adjusted changes (95% CI) | P |
|---|---|---|---|---|
| vWF activity (%) | ||||
| UACR, mg/g | 8.3 (4.1, 12.5) | <0.001 | 4.8 (0.9, 9.4) | 0.040 |
| eGFR, ml/min per 1.73 m2 | 11.0 (6.2, 15.8) | <0.001 | 6.4 (1.0, 11.8) | 0.020 |
| Factor VIII (%) | ||||
| UACR, mg/g | 6.3 (3.1, 9.5) | <0.001 | 4.2 (1.0, 7.3) | 0.011 |
| eGFR, ml/min per 1.73 m2 | 6.6 (3.4, 9.8) | 0.017 | 3.9 (0.7, 7.2) | 0.018 |
Reported for a 10-U decrease of eGFR or 88.5-U increase of UACR. For UACR, to convert from milligrams per gram to milligrams per millimole, multiply by 0.113;
bAdjusted for age, sex, mean arterial pressure, body mass index, hemoglobin, serum albumin, cholesterol, triglycerides, and UACR;
Adjusted for age, sex, mean arterial pressure, body mass index, hemoglobin, serum albumin, cholesterol, triglycerides, and eGFR.
Figure 2Main effect and interaction between 2 factors: CKD and UACR. (A) Effect of CKD and UACR on vWF activity. (B) Effect of CKD and UACR on vWF Ag. (C) Effect of CKD and UACR on factor VIII.
Figure 3Inflammatory biomarkers associated with level of eGFR and UACR group. (A) Effect of CKD and UACR on Interleukin-2. (B) Effect of CKD and UACR on log (Interleukin-6). (C) Effect of CKD and UACR on superoxide dismutase.